Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of tofacitinib versus ciclosporin in renal transplant recipients
2008-002345-23Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of tofacitinib and cyclosporine in kidney transplant immunosuppression and Acute renal rejection (ARR) (2 arms), sponsored by Pfizer. Primary endpoints: Long-term safety and efficacy, Adverse events and 4 more. Started Sep 2008; status: completed.
02
Drugs
tofacitinibcyclosporine
03
Conditions
kidney transplant immunosuppressionAcute renal rejection (ARR)
Beyond the preview
Go deeper on 2008-002345-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002345-23.